137 related articles for article (PubMed ID: 16462681)
1. [Treatment of hypereosinophilia].
Charlanne H; Prin L
Presse Med; 2006 Jan; 35(1 Pt 2):167-72. PubMed ID: 16462681
[TBL] [Abstract][Full Text] [Related]
2. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
Kalac M; Quintás-Cardama A; Vrhovac R; Kantarjian H; Verstovsek S
Cancer; 2007 Sep; 110(5):955-64. PubMed ID: 17654661
[TBL] [Abstract][Full Text] [Related]
3. [Hypereosinophilic syndrome--recent developments in diagnosis and treatment].
Hellmich B; Holl-Ulrich K; Gross WL
Dtsch Med Wochenschr; 2007 Sep; 132(37):1892-6. PubMed ID: 17823882
[TBL] [Abstract][Full Text] [Related]
4. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
Borbényi Z
Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
[TBL] [Abstract][Full Text] [Related]
5. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
Tefferi A; Gotlib J; Pardanani A
Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
[TBL] [Abstract][Full Text] [Related]
6. Novel therapies for hypereosinophilic syndromes.
Antoniu SA
Neth J Med; 2010 Aug; 68(1):304-10. PubMed ID: 20739727
[TBL] [Abstract][Full Text] [Related]
7. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.
Roufosse F; Goldman M; Cogan E
Semin Respir Crit Care Med; 2006 Apr; 27(2):158-70. PubMed ID: 16612767
[TBL] [Abstract][Full Text] [Related]
8. The results of imatinib therapy for patients with primary eosinophilic disorders.
Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
[No Abstract] [Full Text] [Related]
9. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2015 Nov; 90(11):1077-89. PubMed ID: 26486351
[TBL] [Abstract][Full Text] [Related]
10. Clinical management of the hypereosinophilic syndromes.
Cogan E; Roufosse F
Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis of non-parasitic hypereosinophilia].
Kahn JE; Girszyn N; Blétry O
Presse Med; 2006 Jan; 35(1 Pt 2):144-52. PubMed ID: 16462679
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes.
Helbig G; Kyrcz-Krzemień S
Pol Arch Med Wewn; 2011; 121(1-2):44-52. PubMed ID: 21346698
[TBL] [Abstract][Full Text] [Related]
13. [Hematological disorders and hypereosinophilias].
Malfuson JV; Fagot T; Konopacki J; Mangouka L; Souleau B; de Revel T
Rev Med Interne; 2009 Apr; 30(4):322-30. PubMed ID: 19201511
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary arterial hypertension and chronic myeloproliferative disorders.
Di Stefano F
Am J Respir Crit Care Med; 2006 Sep; 174(5):616. PubMed ID: 16931646
[No Abstract] [Full Text] [Related]
15. Chronic myeloid leukemia with pregnancy: Successful management of pregnancy and delivery with hydroxyurea and imatinib continued till delivery.
Yadav U; Solanki SL; Yadav R
J Cancer Res Ther; 2013; 9(3):484-6. PubMed ID: 24125987
[TBL] [Abstract][Full Text] [Related]
16. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
[TBL] [Abstract][Full Text] [Related]
17. Metastatic uterine leiomyosarcoma and eosinophilia.
Ksienski D; Cheung WY
Obstet Gynecol; 2011 Feb; 117(2 Pt 2):459-461. PubMed ID: 21252788
[TBL] [Abstract][Full Text] [Related]
18. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
[TBL] [Abstract][Full Text] [Related]
19. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract][Full Text] [Related]
20. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]